Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
KP 1339 × Gastrointestinal × 90 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡